SEK582.50
2.28% today
Stockholm, Apr 01, 05:29 pm CET
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Camurus Stock price

SEK582.50
-89.00 13.25% 1M
-64.00 9.90% 6M
+17.00 3.01% YTD
+75.00 14.78% 1Y
+404.60 227.43% 3Y
+515.90 774.62% 5Y
+516.50 782.58% 10Y
Stockholm, Closing price Tue, Apr 01 2025
+13.00 2.28%
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Key metrics

Market capitalization SEK33.53b
Enterprise Value SEK30.70b
P/E (TTM) P/E ratio 77.50
EV/FCF (TTM) EV/FCF 85.18
EV/Sales (TTM) EV/Sales 16.44
P/S ratio (TTM) P/S ratio 17.95
P/B ratio (TTM) P/B ratio 10.19
Revenue growth (TTM) Revenue growth 8.78%
Revenue (TTM) Revenue SEK1.87b
EBIT (operating result TTM) EBIT SEK470.73m
Free Cash Flow (TTM) Free Cash Flow SEK360.38m
Cash position SEK2.85b
EPS (TTM) EPS SEK7.35
P/E forward 33.13
P/S forward 11.76
EV/Sales forward 10.77
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Camurus forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Camurus forecast:

Buy
67%
Hold
33%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,868 1,868
9% 9%
100%
- Direct Costs 144 144
6% 6%
8%
1,723 1,723
9% 9%
92%
- Selling and Administrative Expenses 569 569
39% 39%
30%
- Research and Development Expense 669 669
7% 7%
36%
485 485
11% 11%
26%
- Depreciation and Amortization 15 15
5% 5%
1%
EBIT (Operating Income) EBIT 471 471
12% 12%
25%
Net Profit 428 428
1% 1%
23%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 223
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today